Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)

View ORCID ProfileThiago Cerqueira-Silva, Vinicius de Araújo Oliveira, Julia Pescarini, Juracy Bertoldo Júnior, Tales Mota Machado, Renzo Flores Ortiz, Gerson Penna, Maria Yury Ichihara, Jacson Venâncio de Barros, Viviane S. Boaventura, Mauricio L. Barreto, Guilherme Loureiro Werneck, Manoel Barral-Netto
doi: https://doi.org/10.1101/2021.08.21.21261501
Thiago Cerqueira-Silva
1LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thiago Cerqueira-Silva
Vinicius de Araújo Oliveira
1LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Pescarini
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
4London School of Hygiene and Tropical Medicine, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juracy Bertoldo Júnior
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tales Mota Machado
5Universidade Federal de Ouro Preto, Ouro Preto, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Renzo Flores Ortiz
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerson Penna
6Núcleo de Medicina Tropical, Universidade de Brasília. Escola Fiocruz de Governo, Fiocruz Brasilia. Brasilia, DF, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Yury Ichihara
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacson Venâncio de Barros
7Department of Health Informatics, Ministry of Health, Brasília, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane S. Boaventura
1LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mauricio L. Barreto
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guilherme Loureiro Werneck
8Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manoel Barral-Netto
1LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Fiocruz, Salvador, Bahia, Brazil
2Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil
3Center for Data Integration and Knowledge for Health (Cidacs / IGM / Fiocruz), Salvador, Bahia, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: manoel.barral@fiocruz.br
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background High rates of virus transmission and the presence of variants of concern can affect vaccine effectiveness (VE). Both conditions occur in low-income countries, which primarily use viral vector or inactivated virus vaccine technologies. However, few VE analyses have been conducted in such countries, and most lack the power to evaluate effectiveness in subgroups, such as the elderly.

Methods The present retrospective cohort study evaluated the effectiveness of Vaxzevria and CoronaVac vaccines for COVID-19-related infection in 60,577,870 Brazilian vaccinees from January 18 to June 30, 2021.

Study outcomes included documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Covid-19–related hospitalization, ICU admission and death. We estimated VE for each outcome as one minus the hazard ratio using Cox regression adjusted for age, sex, Brazilian deprivation index, and month/region of dose administration.

Results Vaccination with Vaxzevria or CoronaVac was found to be effective against SARS-CoV-2 infection and highly effective against hospitalization, ICU admission and death in individuals up to 79 years. From 80-89 years of age, 91.2 (95CI: 89.1-92.9) VE against death was seen in Vaxzevria-vaccinated individuals versus 67.3 (95CI: 63.6-70.6) for Coronvac. Above 90 years, 70.5 (95CI: 51.4-82.1) protection was conferred to Vaxzevria-vaccinated individuals versus 35.4 (95CI: 23.8-45.1) in Coronavac-vaccinated individuals

Conclusions Both vaccines demonstrated overall effectiveness against severe COVID-19 up to 80 years of age. Our results suggest that individuals aged 90 years or older may benefit from an expedited third booster dose. Ongoing evaluations, including any additional vaccines authorized, are crucial to monitoring long-term vaccine effectiveness.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

FUNDING This study was partially supported by a donation from the "Fazer o bem faz bem"-JBS program.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308). The study was considered exempt from informed consent; no human health risks were identified. All work presented here used unidentified secondary data in accordance with the Brazilian Personal Data Protection General Law (LGPD). Data was manipulated in a secure computing environment, ensuring protection against data leakage and records reidentification.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

We used third-party data, provided by the Brazilian Ministry of Health. Any request for access to the data shall be directed to DATASUS - Ministry of Health Brazil: https://datasus.saude.gov.br/

https://datasus.saude.gov.br/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 25, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)
Thiago Cerqueira-Silva, Vinicius de Araújo Oliveira, Julia Pescarini, Juracy Bertoldo Júnior, Tales Mota Machado, Renzo Flores Ortiz, Gerson Penna, Maria Yury Ichihara, Jacson Venâncio de Barros, Viviane S. Boaventura, Mauricio L. Barreto, Guilherme Loureiro Werneck, Manoel Barral-Netto
medRxiv 2021.08.21.21261501; doi: https://doi.org/10.1101/2021.08.21.21261501
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19)
Thiago Cerqueira-Silva, Vinicius de Araújo Oliveira, Julia Pescarini, Juracy Bertoldo Júnior, Tales Mota Machado, Renzo Flores Ortiz, Gerson Penna, Maria Yury Ichihara, Jacson Venâncio de Barros, Viviane S. Boaventura, Mauricio L. Barreto, Guilherme Loureiro Werneck, Manoel Barral-Netto
medRxiv 2021.08.21.21261501; doi: https://doi.org/10.1101/2021.08.21.21261501

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1958)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10808)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)